Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential.

Low-risk patients suffering from prostate cancer (PCa) are currently placed under active surveillance rather than undergoing radical prostatectomy. However, clear parameters for selecting the right patient for each strategy are not available, and new biomarkers and treatment modalities are needed.

Low-molecular-weight protein tyrosine phosphatase (LMWPTP) could present such a target

To correlate expression levels of LMWPTP in primary PCa to clinical outcome, and determine the role of LMWPTP in prostate tumor cell biology

Acid phosphatase 1, soluble (ACP1) expression was analyzed on microarray data sets, which were subsequently used in Ingenuity Pathway Analysis Immunohistochemistry was performed on a tissue microarray containing material of 481 PCa patients whose clinicopathologic data were recorded PCa cell line models were used to investigate the role of LMWPTP in cell proliferation, migration, adhesion, and anoikis resistance

The association between LMWPTP expression and clinical and pathologic outcomes was calculated using chi-square correlations and multivariable Cox regression analysis Functional consequences of LMWPTP overexpression or downregulation were determined using migration and adhesion assays, confocal microscopy, Western blotting, and proliferation assays

LMWPTP expression was significantly increased in human PCa and correlated with earlier recurrence of disease (hazard ratio [HR]:1 99; p

Overexpression of LMWPTP in PCa confers a malignant phenotype with worse clinical outcome Prospective follow-up should determine the clinical potential of LMWPTP overexpression

These findings implicate low-molecular-weight protein tyrosine phosphatase as a novel oncogene in prostate cancer and could offer the possibility of using this protein as biomarker or target for treatment of this disease

European urology 2015 Jul 06 [Epub ahead of print]

Roberta R Ruela-de-Sousa, Elmer Hoekstra, A Marije Hoogland, Karla C Souza Queiroz, Maikel P Peppelenbosch, Andrew P Stubbs, Karin Pelizzaro-Rocha, Geert J L H van Leenders, Guido Jenster, Hiroshi Aoyama, Carmen V Ferreira, Gwenny M Fuhler

Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Biochemistry and Tissue Biology, University of Campinas, Campinas, Brazil , Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands , Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands , Department of Biochemistry and Tissue Biology, University of Campinas, Campinas, Brazil; Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands , Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands , Department of Bioinformatics, Erasmus University Medical Center, Rotterdam, The Netherlands , Department of Biochemistry and Tissue Biology, University of Campinas, Campinas, Brazil , Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands , Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands , Department of Biochemistry and Tissue Biology, University of Campinas, Campinas, Brazil , Department of Biochemistry and Tissue Biology, University of Campinas, Campinas, Brazil , Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands 

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe